cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)

External References:      Wikipedia GeneCards HUGO COSMIC Google Scholar

NCBI Description of CDKN2A

This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene.

Community Annotation of CDKN2A Add / Edit CDKN2A: Annotations

No community annotations yet for CDKN2A.
Sort mutations by: Tumor type  Mutation type  Position  
Straightedge cursor Expand

Figure notes

• "Mouse over" a mutation to see details.
• Missense green saturation indicates evolutionary conservation of the mutated positions.
• Red hashes in protein strip are splice sites.
• Blue-white-red bars are log2 copy ratio distributions (–1 to +1) from Zack et al. (2013).


CDKN2A is highly significantly mutated in
Head and neck
78 patients (20%)
Lung squamous cell carcinoma
28 patients (15%)
18 patients (15%)
Esophageal adenocarcinoma
9 patients (6%)
Lung adenocarcinoma
23 patients (5%)
combined cohort
170 patients (3%)
CDKN2A is significantly mutated in
CDKN2A is near significance in
3 patients (3%)

Click on a tumor type to see its full list of significant genes.

Data details

Mutation list for CDKN2A